JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Journal of Clinical Pathology 2007;60:936-938; doi:10.1136/jcp.2006.044750
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ngo, N.
Right arrow Articles by Naresh, K. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ngo, N.
Right arrow Articles by Naresh, K. N

CASE REPORTS

Leucocyte common antigen (CD45) and CD5 positivity in an "undifferentiated" carcinoma: a potential diagnostic pitfall

Nyethane Ngo1, Kaushik Patel2, Peter G Isaacson3, Kikkeri N Naresh4

1 Department of Histopathology, Hammersmith Hospital, Imperial College, London, UK
2 Department of Histopathology, Kingston Hospital, London, UK
3 Department of Histopathology, University College, London, UK
4 Department of Histopathology, Hammersmith Hospital, Imperial College, London, UK

Correspondence to:
Professor K N Naresh
Department of Histopathology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK; k.naresh@imperial.ac.uk 3 November 2006

The first 150 words of the full text of this article appear below.

CD45 is a transmembrane protein tyrosine phosphatase located on most haematopoietic cells. It has several isoforms, and haematopoietic cells express one or more of the isoforms—CD45RO, CD45RA and CD45RB.1,2 CD45 immunoreactivity is recognised to be highly specific for non–Hodgkin’s lymphomas.3,4 CD45-expressing non-haemopoietic tumours are very rare. This was first noted by McDonnell et al5 in 1987, who reported a primitive sarcoma expressing CD45. Subsequently, Nandedkar et al6 reported three cases of undifferentiated large-cell, possibly neuroendocrine, carcinomas expressing CD45. Two of them were lymph node metastasis and one was a pulmonary tumour. All the three cases expressed both CD45 and cytokeratin. Two of the cases behaved in an aggressive manner.6

In contrast to CD45, CD5 is expressed in thymic carcinoma and malignant mesothelioma.7,8 To the best of our knowledge, this is the first reported case of a carcinoma expressing both CD45 and CD5.


Case report
We report a patient in their 60s who . . . [Full text of this article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.